

In re Application 10/500,784  
Response to Office Action dated Feb 23, 2007  
Page 2 of 5

RECEIVED  
CENTRAL FAX CENTER

JUN 25 2007

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Please cancel claims 1-36.

37. (Currently Amended) An isolated antibody, or binding fragment thereof, specific for the C-terminal region of SEQ ID NO 2 consisting of amino acid residues 105-187.
38. (Previously Presented) The antibody of claim 37, wherein said antibody is monoclonal.
39. (Currently Amended) The antibody of claim 38, wherein said antibody is humanized[,,] or human[,,] bispecific, or a heteroconjugate.
40. (Withdrawn) A method for diagnosing the predisposition of a patient to develop an MCEMP-1 related disease comprising:
  - a. collecting a sample known to contain mast cells from a patient;
  - b. detecting the presence of MCEMP-1 protein using the antibody of claim 37; and
  - c. comparing the level of MCEMP-1 protein in said patient to a defined or tested level established for normal samples, wherein an elevated level of MCEMP-1 is indicative of an MCEMP-1 related disease..
41. (Withdrawn) A method for diagnosing the predisposition of a patient to develop a disease associated with overexpression of MCEMP-1, comprising:
  - a. collecting a sample known to contain mast-cells from a patient;
  - b. analyzing the sample for the amount of MCEMP-1 using the antibody of claim 37; and
  - c. predicting the predisposition of the patient to certain immune diseases based upon the change in the amount of MCEMP-1 in the sample compared to a defined or tested level established for normal patient samples.
42. (Withdrawn) A method for diagnosing an MCEMP-1 related disease comprising:
  - a. collecting a cell, tissue, or body fluid sample known to contain mast cells from a patient;
  - b. detecting the presence of MCEMP-1 protein using the antibody of claim 37; and
  - c. comparing the level of MCEMP-1 protein in said patient to a defined or tested level established for normal patient samples, wherein an elevated level of MCEMP-1 is indicative of an MCEMP-1 related disease.
43. (NEW) The antibody of claim 37, wherein said antibody is a heteroconjugate.
44. (NEW) The antibody of claim 37, wherein said antibody is bispecific.